Surgical Management of Hepatocellular Carcinoma

  • Steven A. Curley
Part of the M.D. Anderson Solid Tumor Oncology Series book series (MDA)


Hepatocellular carcinoma (HCC) is one of the 10 most common cancers in the world. Although relatively uncommon in Western Countries, HCC is probably the most common solid cancer in the world.1,2 Worldwide annual incidence of HCC is estimated to be at least one million new patients.3–5 HCC is also one of the most lethal human malignancies, with a mortality index of 0.94.6


Hepatocellular Carcinoma Liver Resection Hepatic Resection Cirrhotic Patient Primary Liver Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Beasley R. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 61:1942, 1988PubMedCrossRefGoogle Scholar
  2. 2.
    Di Bisceglie A. Hepatocellular carcinoma: molecular biology of its growth and relationship to hepatitis B virus infection. Med Clin North Am 73:985, 1989PubMedGoogle Scholar
  3. 3.
    Arya S, Ashraf S, Parande C, et al. Hepatitis B and delta markers in primary hepatocellular carcinoma patients in the Gizan area of Saudi Arabia. APMIS Suppl 3:30, 1988PubMedGoogle Scholar
  4. 4.
    Bridbord K. Pathogenesis and prevention of hepatocellular carcinoma. Cancer Detect Prev 14:191, 1989PubMedGoogle Scholar
  5. 5.
    Di Bisceglie A, Rustgi V, Hoofnagle J, et al. NIH conference on hepatocellular carcinoma. Ann Intern Med 108:390, 1988PubMedGoogle Scholar
  6. 6.
    Rustgi V. Epidemiology of hepatocellular cancer. Ann Intern Med 108:390, 1988PubMedGoogle Scholar
  7. 7.
    Anonymous. Hepatocellular cancer: differences between high and low incidence regions. Lancet 2:1183, 1987Google Scholar
  8. 8.
    Zuckerman A. Prevention of primary liver cancer by immunization. Cancer Detect Prev 14:309, 1989PubMedGoogle Scholar
  9. 9.
    Lindtjorn B. Cancer in southern Ethiopia. J Trop Med Hyg 90:181, 1987PubMedGoogle Scholar
  10. 10.
    Beasley RP, Hwang LY. Epidemiology of hepatocellular carcinoma. In: Vyas GN, Dienstag JL, Hoofnagle JH (eds) Viral Hepatitis and Liver Disease. Orlando, Grune & Stratton, 1984, p. 209Google Scholar
  11. 11.
    Falk H. Liver. In: Schottenfeld D, Fraumeni J (eds) Cancer Epidemiology and Prevention. Philadelphia, Saunders, 1982, p. 668Google Scholar
  12. 12.
    Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22 707 men in Taiwan. Lancet 2:1129, 1981PubMedCrossRefGoogle Scholar
  13. 13.
    Esteban J, Gonzalez A, Hernandez J, et al. Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis. N Engl J Med 323:1107, 1990PubMedCrossRefGoogle Scholar
  14. 14.
    Verbaan H, Widell A, Lindgren S, et al. Hepatitis C in chronic liver disease: an epidemiological study based on 566 consecutive patients undergoing liver biopsy during a 10-year period. J Intern Med 232:33, 1992PubMedCrossRefGoogle Scholar
  15. 15.
    Tanaka H, Hiyama T, Tsukuma H, et al. Cumulative risk of hepatocellular carcinoma in hepatitis C virus carriers: statistical estimations from cross-sectional data. Jpn J Cancer Res 85:485, 1994PubMedCrossRefGoogle Scholar
  16. 16.
    Tarao K, Ohkawa S, Shimizu A, et al. Significance of hepatocellular proliferation in the development of hepatocellular carcinoma from anti-hepatitis C virus-positive cirrhotic patients. Cancer 73:1149, 1994PubMedCrossRefGoogle Scholar
  17. 17.
    Lisker-Melman M, Martin P, Hoofnagle J. Conditions associated with hepatocellular carcinoma. Med Clin North Am 73:999, 1989PubMedGoogle Scholar
  18. 18.
    Sinha S, Webber C, Marshall CJ, et al. Activation of ras oncogene in aflatoxin-induced rat liver carcinogenesis. Proc Natl Acad Sci USA 85:3673, 1988PubMedCrossRefGoogle Scholar
  19. 19.
    McMahon G, Davis EF, Huber LJ, et al. Characterization of c-Ki-ras and N-ras oncogenes in aflatoxin B,-induced rat liver tumors. Proc Natl Acad Sci USA 87:1104, 1990PubMedCrossRefGoogle Scholar
  20. 20.
    Aguilar F, Hussain SP, Cerutti P: Aflatoxin B1, induces the transversion of GÙT in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci USA 90:8586, 1993PubMedCrossRefGoogle Scholar
  21. 21.
    Hardell L, Bengtsson NO, Jonsson U, et al. Aetiological aspects on primary liver cancer with special regard to alcohol, organic solvent and acute intermittent porphyria: an epidemiological investigation. Br J Cancer 50:389, 1984PubMedCrossRefGoogle Scholar
  22. 22.
    Boutron M, Faivre J, Milan C, et al. Primary liver cancer in Cote D-Or (France). Int J Epidemiol 17:21, 1988PubMedCrossRefGoogle Scholar
  23. 23.
    Rockelein G, Hecken-Emmel M. Risk factors of hepatocellular carcinoma in Germany: hepatitis B or liver cirrhosis? Hepatogastroenterology 35:151, 1988PubMedGoogle Scholar
  24. 24.
    Fleisher JM. Occupational and non-occupational risk factors in relation to an excess of primary liver cancer observed among residents of Brooklyn, New York. Cancer 65:180, 1990PubMedCrossRefGoogle Scholar
  25. 25.
    Hollands M, Huang J, Adams W, Little J. Hepatocellular carcinoma in western Sydney. Ann Acad Med Singapore 17:89, 1988PubMedGoogle Scholar
  26. 26.
    Tabor E. Hepatocellular carcinoma: possible etiologies in patients without serologic evidence of hepatitis B virus infection. J Med Virol 27:1 1989PubMedCrossRefGoogle Scholar
  27. 27.
    Polio J, Enriquez RE, Chow A, et al. Hepatocellular carcinoma as a complication of Wilson’s disease: case report and review of the literature. J Clin Gastroenterol 11:220, 1989PubMedCrossRefGoogle Scholar
  28. 28.
    Okuda H, Obata H, Nakanishi T, et al. Production of abnormal prothrombin (des-QQQ-carboxy prothrombin) by hepatocellular carcinoma: a clinical and experimental study. J Hepatol 4:357, 1987PubMedCrossRefGoogle Scholar
  29. 29.
    Suehiro T, Sugimachi K, Matsumata T, et al. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Cancer 73:2464, 1994PubMedCrossRefGoogle Scholar
  30. 30.
    Kasahara A, Hayashi N, Fusamoto H, et al. Clinical evaluation of plasma descarboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci 38:2170, 1993PubMedCrossRefGoogle Scholar
  31. 31.
    Yamashita F, Tanaka M, Satomura S, Tanikawa K. Prognostic significance of Lens culinaris agglutinin A-reactive α-fetoprotein in small hepatocellular carcinoma. Gastroenterology 111:996, 1996PubMedCrossRefGoogle Scholar
  32. 32.
    Yamazaki H, Oi H, Matsumoto K, et al. Biphasic changes in serum hepatocyte growth factor after transarterial chemoembolization therapy for hepatocellular carcinoma. Cytokine 8:178, 1996PubMedCrossRefGoogle Scholar
  33. 33.
    Soini Y, Virkajärvi N, Raunio H. Pääkkö P. Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis. J Clin Pathol 49:470, 1996PubMedCrossRefGoogle Scholar
  34. 34.
    Tsutsumi M, Sakamuro D, Takada A, et al. Detection of a unique QQQ-glutamyl transpeptidase messenger RNA species closely related to the development of hepatocellular carcinoma in humans: a new candidate for early diagnosis of hepatocellular carcinoma. Hepatology 23:1093, 1996PubMedGoogle Scholar
  35. 35.
    Liaw YF, Tai DI, Chem TJ, et al. Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic fibrosis and hepatocellular carcinoma. Liver 6:133, 1986PubMedGoogle Scholar
  36. 36.
    Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels: analysis of 606 patients. Cancer 64:1700, 1989PubMedCrossRefGoogle Scholar
  37. 37.
    Golondi L, Benzi G, Santi V, et al. Relationship between α-fetoprotein serum levels, tumour volume and growth rate of hepatocellular carcinoma in a western population. Ital J Gastroenterol 22:190, 1990Google Scholar
  38. 38.
    Thung SN, Gerber MA, Sarno E, Popper H. Distribution of five antigens in hepatocellular carcinoma. Lab Invest 41:101, 1979PubMedGoogle Scholar
  39. 39.
    Rolfes DB. Fibrolamellar carcinoma of the liver. In: Okuda K, Ishak KG (eds) Neoplasms of the Liver. Tokyo, Springer, 1987 p. 137Google Scholar
  40. 40.
    Izzo F, Curley SA, Maio P, et al. Soluble interleukin-2 receptor levels correlate with severity of hepatitis C virus liver injury and risk to develop hepatocellular cancer. Surgery 120:100, 1996PubMedCrossRefGoogle Scholar
  41. 41.
    Kobayashi K, Sugimoto T, Makino H, et al. Screening methods for early detection of hepatocellular carcinoma. Hepatology 5:1100, 1985PubMedCrossRefGoogle Scholar
  42. 42.
    Sell S. Detection of cancer by tumor markers in the blood: a view to the future. Crit Rev Oncog 4:419, 1993PubMedGoogle Scholar
  43. 43.
    Cottone M, Turri M, Caltagirone M, et al. Early detection of hepatocellular carcinoma associated with cirrhosis by ultrasound and alpha fetoprotein: a prospective study. Hepatogastroenterology 35:101, 1989Google Scholar
  44. 44.
    Liaw YF, Tai DI Chu CM, et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis: a prospective study. Gastroenterology 90:263, 1989Google Scholar
  45. 45.
    Maringhini A, Cottone M, Sciarrino E, et al. Ultrasonography and alpha-fetoprotein in diagnosis of hepatocellular carcinoma in cirrhosis. Dig Dis Sci 33:47, 1988PubMedCrossRefGoogle Scholar
  46. 46.
    Colombo M, de Franchis R, del Nino E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 325:675, 1991PubMedCrossRefGoogle Scholar
  47. 47.
    Curley SA, Izzo F, DeBellis M, Cremona F, Parisi V. Identification and screening of 416 patients with chronic hepatitis at high risk to develop hepatocellular cancer. Ann Surg 222:375, 1995PubMedCrossRefGoogle Scholar
  48. 48.
    Izzo F, Cremona F, Ruffolo F, et al. Outcome of 67 hepatocellular cancer patients detected during screening of 1,125 chronic hepatitis patients. Ann Surg (in press)Google Scholar
  49. 49.
    Unoura M, Kaneko S, Matsushita E, et al. High-risk groups and screening strategies for early detection of hepatocellular carcinoma in patients with chronic liver disease. Hepatogastroenterology 40:305, 1993PubMedGoogle Scholar
  50. 50.
    Baron RL. Detection of liver neoplasms: techniques and outcomes. Abdom Imaging 19:320, 1994PubMedCrossRefGoogle Scholar
  51. 51.
    Stone HH, Long WD, Smith RB, et al. Physiologic considerations in major hepatic resection. Am J Surg 117:78, 1969PubMedCrossRefGoogle Scholar
  52. 52.
    Chlebowski RT, Tong M, Weissman J, et al. Hepatocellular carcinoma: diagnostic and prognostic features in North American patients. Cancer 53:2701, 1984PubMedCrossRefGoogle Scholar
  53. 53.
    Lim RC Jr, Bongard FS. Hepatocellular carcinoma: changing concepts in diagnosis and management. Arch Surg 119:637, 1984PubMedCrossRefGoogle Scholar
  54. 54.
    Lung G, Florence L, Hohgnasen K. Hepatocellular carcinoma: a 5-year institutional experience. Am J Surg 149:591, 1985CrossRefGoogle Scholar
  55. 55.
    Ottow RT, August DA, Sugarbaker PH. Surgical therapy of liver cancer. In: Bottino JC, Opfell RW, Muggia FM (eds) Liver Cancer. Boston, Martinus Nijhoff, 1985, p. 99CrossRefGoogle Scholar
  56. 56.
    Lee CS, Chi-Ching C, Lin TY. Partial hepatectomy on cirrhotic liver with a right lateral tumor. Surgery 98:942, 1985PubMedGoogle Scholar
  57. 57.
    Noguchi T, Imai T, Mizumoto R. Preoperative estimation of surgical risk of hepatectomy in cirrhotic patients. Hepatogastroenterology 37:165, 1990PubMedGoogle Scholar
  58. 58.
    Gholson CF, Provenza JM, Bacon BR. Hepatologic considerations in patients with parenchymal liver disease undergoing surgery. Am J Gastroenterol 85:487, 1990PubMedGoogle Scholar
  59. 59.
    Paumgartner G, Probst P, Kraines R, Leevy CM. Kinetics of indocyanine green removal from the blood. Ann NY Acad Sci 170:134, 1970CrossRefGoogle Scholar
  60. 60.
    Moody FG, Rikkers LF, Aldrete JS. Estimation of the functional reserve of human liver. Ann Surg 180:592, 1974PubMedCrossRefGoogle Scholar
  61. 61.
    Barbara JC, Poupon RE, Jaillon R, et al. Intrinsic hepatic clearance and Child-Turcotte classification for assessment of liver function in cirrhosis. J Hepatol 1:253, 1985CrossRefGoogle Scholar
  62. 62.
    Matsumata T, Kanematsu T, Yoshida Y, et al. The indocyanine green test enables prediction of postoperative complications after hepatic resection. World J Surg 11:678, 1987PubMedCrossRefGoogle Scholar
  63. 63.
    Kanematsu T, Takenaka K, Matsumata T, et al. Limited hepatic resection effective for selected cirrhotic patients with primary liver cancer. Ann Surg 199:51, 1984PubMedCrossRefGoogle Scholar
  64. 64.
    Yamanaka N, Okamoto E, Toyosaka A, et al. Prognostic factors after hepatectomy for hepatocellular carcinomas: a univariate and multivariate analysis. Cancer 65:1104, 1990PubMedCrossRefGoogle Scholar
  65. 65.
    Tsuzuki T, Sugioka A, Ueda M. Hepatic resection for hepatocellular carcinoma. Surgery 107:511, 1990PubMedGoogle Scholar
  66. 66.
    Mizumoto R, Kawarada Y, Noguchi T. Preoperative estimation of operative risk in liver surgery, with special reference to functional reserve of the remant liver following major hepatic resection. Jpn J Surg 9:343, 1979PubMedCrossRefGoogle Scholar
  67. 67.
    Okamoto E, Kyo A, Yamanaka N, et al. Prediction of the safe limits of hepatectomy by combined volumetric and functional measurements in patients with impaired hepatic function. Surgery 95:586, 1984PubMedGoogle Scholar
  68. 68.
    Reichen J, Arts B, Schafroth U, et al. Aminopyrine N-demethylation by rats with liver cirrhosis; evidence for the intact cell hypothesis: a morphometric-functional study. Gastroenterology 93:719, 1987PubMedGoogle Scholar
  69. 69.
    Reichen J, Egger B, Ohara N, et al. Determinants of hepatic function in liver cirrhosis in the rate: multvariate analysis. J Clin Invest 82:2069, 1988PubMedCrossRefGoogle Scholar
  70. 70.
    Henry DA, Kitchingman G, Langman MJ. 14C-Aminopyrine breath analysis and conventional biochemical tests as predictors of survival in cirrhosis. Dig Dis Sci 30:813, 1985PubMedCrossRefGoogle Scholar
  71. 71.
    Lashner BA, Jonas RB, Tang HS, et al. Chronic hepatitis: disease factors at diagnosis predictive of mortality. Am J Med 85:609, 1988PubMedCrossRefGoogle Scholar
  72. 72.
    Gill RA, Goodman MW, Golfus GR, et al. Aminopyrine breath test predicts surgical risk for patients with liver disease. Ann Surg 198:701, 1983PubMedCrossRefGoogle Scholar
  73. 73.
    Scudamore CH, Hemming A, Chow Y Resection of hepatocellular carcinoma in the cirrhotic patient. In: Tabor E, Di Bisceglie AM, Purcell RH (eds) Etiology, Pathology, and Treatment of Hepatocellular Carcinoma in North America. The Woodlands, Portfolio Publishing, 1991, p. 293Google Scholar
  74. 74.
    Oellerich M, Burdelski M, Lautz HU, et al. Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis. Ther Drug Monit 12:219, 1990PubMedCrossRefGoogle Scholar
  75. 75.
    Miyoshi S, Minami Y, Kawata S, et al. Changes in hepatic functional reserve after transcatheter embolization of hepatocellular carcinoma. J Hepatol 6:332, 1988PubMedCrossRefGoogle Scholar
  76. 76.
    Fujio N, Saiki K, Kinoshita H, et al. Results of treatment of patients with hepatocellular carcinoma with severe cirrhosis of the liver. World J Surg 13:211, 1989PubMedCrossRefGoogle Scholar
  77. 77.
    Yamanaka N, Okamoto E, Kuwata K, Tanaka N. A multiple regression equation for prediction of posthepatectomy liver failure. Ann Surg 200:658, 1984PubMedCrossRefGoogle Scholar
  78. 78.
    Liver Cancer Study Group of Japan. Primary liver cancer in Japan: clinico-pathologic features and results of surgical treatment. Ann Surg 211:277, 1990Google Scholar
  79. 79.
    Choi TK, Lai Edward CS, Fan ST, et al. Results of surgical resection for hepatocellular carcinoma. Hepatogastroenterology 37:172, 1990PubMedGoogle Scholar
  80. 80.
    Nagorney DM, van Heerden JA, Ilstrup DM, Adson MA. Primary hepatic malignancy: surgical management and determinants of survival. Surgery 106:740, 1989PubMedGoogle Scholar
  81. 81.
    Paquet K-J, Koussouris P, Mercado MA, et al. Limited hepatic resection for selected cirrhotic patients with hepatocellular or cholangiocellular carcinoma: a prospective study. Br J Surg 78:459, 1991PubMedCrossRefGoogle Scholar
  82. 82.
    Franco D, Capussotti L, Smadja C, et al. Resection of hepatocellular carcinoma: results in 72 European patients with cirrhosis. Gastroenterology 98:733, 1990PubMedGoogle Scholar
  83. 83.
    Cottone M, Virdone R, Fusco G, et al. Asymptomatic hepatocellular carcinoma in Child’s A cirrhosis: a comparison of natural history and surgical treatment. Gastroenterology 96:1566, 1989PubMedGoogle Scholar
  84. 84.
    Ringe B, Pichlmayr R, Wittekind C, Tusch G. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 15:270, 1991PubMedCrossRefGoogle Scholar
  85. 85.
    Tsuzuki T, Ogata Y, Iida S, Shimazu M. Hepatic resection in 125 patients. Arch Surg 119:1025, 1984PubMedCrossRefGoogle Scholar
  86. 86.
    Nagao A, Inoue U, Goto S, et al. Hepatic resection for hepatocellular carcinoma: clinical features and long-term prognosis. Ann Surg 205:33, 1987PubMedCrossRefGoogle Scholar
  87. 87.
    Kim ST, Kim KP. Hepatic resections for primary liver cancer. Cancer Chemother Pharmacol 33:S18, 1994PubMedCrossRefGoogle Scholar
  88. 88.
    Kosuge T, Makuuchi M, Takayama T, et al. Long-term results after resection of hepatocellular carcinoma: experience of 480 cases. Hepatogastroenterology 40:328, 1993PubMedGoogle Scholar
  89. 89.
    Nagasue N, Kohno H, Chang Y-C, et al. Liver resection for hepatocellular carcinoma: results of 229 consecutive patients during 11 years. Ann Surg 217:375, 1993PubMedCrossRefGoogle Scholar
  90. 90.
    Ozawa K, Takayasu T, Kumada K, et al. Experience with 225 hepatic resections for hepatocellular carcinoma over a 4-year period. Am J Surg 161:677, 1991PubMedCrossRefGoogle Scholar
  91. 91.
    Lai ECS, You K-T, Ng IOL, Shek TWH. The pathological basis of resection margin for hepatocellular carcinoma. World J Surg 17:786, 1993PubMedCrossRefGoogle Scholar
  92. 92.
    Sugioka A, Tsuzuki T, Kanai T. Postresection prognosis of patients with hepatocellular carcinoma. Surgery 113:612, 1993PubMedGoogle Scholar
  93. 93.
    Parker GA, Lawrence W Jr, Horsley S III et al. Intraoperative ultrasound of the liver affects operative decision making. Ann Surg 209:569, 1989PubMedCrossRefGoogle Scholar
  94. 94.
    Makuuchi M, Hasegawa H, Kamazaki S, et al. The use of operative ultrasound as an aid to liver resection in patients with hepatocellular carcinoma. World J Surg 11:615, 1987PubMedCrossRefGoogle Scholar
  95. 95.
    Clarke MP, Kane RA, Steele G, et al. Prospective comparison of preoperative imaging and intraoperative ultrasonography in the detection of liver tumors. Br J Surg 76:1323, 1989CrossRefGoogle Scholar
  96. 96.
    Sheu JC, Lee CS, Sung IL, et al. Intraoperative hepatic ultrasonography—an indispensable procedure in resection of small hepatocellular carcinomas. Surgery 97:97, 1985PubMedGoogle Scholar
  97. 97.
    Bozzetti F, Gennari L, Regalia E, et al. Morbidity and mortality after surgical resection of liver tumors: analysis of 229 cases. Hepatogastroenterology 39:237, 1992PubMedGoogle Scholar
  98. 98.
    Takenaka K, Kanematsu T, Fukuzawa K, Sugimachi K. Can hepatic failure after surgery for hepatocellular carcinoma in cirrhotic patients be prevented? World J Surg 14:123, 1990PubMedCrossRefGoogle Scholar
  99. 99.
    Bismuth H, Castaing D, Garden OJ. Major hepatic resection under total vascular exclusion. Ann Surg 210:13, 1989PubMedCrossRefGoogle Scholar
  100. 100.
    Delva E, Camus Y, Nordlinger B, et al. Vascular occlusions for liver resections. Ann Surg 209:297, 1989CrossRefGoogle Scholar
  101. 101.
    Kanematsu T, Matsumata T, Takenaka K, et al. Clinical management of recurrent hepatocellular carcinoma after primary resection. Br J Surg 75:203, 1988PubMedCrossRefGoogle Scholar
  102. 102.
    Nagao T, Inoue S, Yoshimi F, et al. Postoperative recurrence of hepatocellular carcinoma. Ann Surg 211:28, 1990PubMedCrossRefGoogle Scholar
  103. 103.
    Huguet C, Bona S, Nordlinger B, et al. Repeat hepatic resection for primary and metastatic carcinoma of the liver. Surg Gynecol Obstet 171:398, 1990PubMedGoogle Scholar
  104. 104.
    Hu R-H, Lee P-H, Yu S-C, et al. Surgical resection for recurrent hepatocellular carcinoma: prognosis and analysis of risk factors. Surgery 120:23, 1996PubMedCrossRefGoogle Scholar
  105. 105.
    Shimada M, Takenaka K, Gion T, et al. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology 111:720, 1996PubMedCrossRefGoogle Scholar
  106. 106.
    Jacob G, Li AKC, Hobbs KEF. A comparison of cryodestruction with excision or infarction of an implanted tumor in rate liver. Cryobiology 21:148, 1984PubMedCrossRefGoogle Scholar
  107. 107.
    Gage AA, Guest K, Montes M, et al. Effect of varying freezing and thawing rates in experimental cryosurgery. Cryobiology 22:175, 1985PubMedCrossRefGoogle Scholar
  108. 108.
    Shier WT. Studies on the mechanisms of mammalian cell killing by a freeze-thaw cycle: conditions that prevent cell killing using nucleated freezing. Cryobiology 22:110, 1988CrossRefGoogle Scholar
  109. 109.
    Gilbert JC, Onik GM, Hoddick WK, Rubinsky B. Real time ultrasonic monitoring of hepatic cryosurgery. Cryobiology 22:319, 1985PubMedCrossRefGoogle Scholar
  110. 110.
    Onik G, Rubinsky B, Zemel R, et al. Ultrasound-guided hepatic cryosurgery in the treatment of metastatic colon carcinoma. Cancer 67:901, 1991PubMedCrossRefGoogle Scholar
  111. 111.
    Zhou XD, Tang ZY, Yu YQ, et al. Clinical evaluation of cryosurgery in the treatment of primary liver cancer: report of 60 cases. Cancer 61:1889, 1988PubMedCrossRefGoogle Scholar
  112. 112.
    Zhou XD, Tang ZY, Yu YQ, et al. The role of cryosurgery in the treatment of hepatic cancer: a report of 113 cases. J Cancer Res Clin Oncol 120:100, 1993PubMedCrossRefGoogle Scholar
  113. 113.
    Stone M J, Klintmalm GBG, Polter D, et al. Liver transplantation for hepatocellular carcinoma. Hepatology 18:218, 1993CrossRefGoogle Scholar
  114. 114.
    Bismuth H, Chiche L, Adam R, et al. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 218:145, 1993PubMedCrossRefGoogle Scholar
  115. 115.
    Yokoyama I, Sheahan DG, Carr B, et al. Clinicopathologic factors affecting patient survival and tumor recurrence after orthotopic liver transplantation for hepatocellular carcinoma. Transplant Proc 23:2194, 1991PubMedGoogle Scholar
  116. 116.
    Carr BI, Selby R, Madariaga J, Iwatsuki S, Starzl TE. Prolonged survival after liver transplantation and cancer chemotheraphy for advanced-stage hepatocellular carcinoma. Transplant Proc 25:1128, 1993PubMedGoogle Scholar
  117. 117.
    Spreafico C, Marchiano A, Regalia E, et al. Chemoembolization of hepatocellular carcinoma in patients who undergo liver transplantation. Radiology 192:687, 1994PubMedGoogle Scholar
  118. 118.
    Stone MJ, Klintmalm GBG, Polter D, et al. Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study in 20 patients. Gastroenterology 104:196, 1993PubMedGoogle Scholar
  119. 119.
    Tang ZY, Yu YQ, Xhou XD, et al. Cytoreduction and sequential resection: a hope for unresectable primary liver cancer. J Surg Oncol 47:27, 1991PubMedCrossRefGoogle Scholar
  120. 120.
    Sitzmann JV, Order SE, Klein JL, et al. Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancer. J Clin Oncol 5:1566, 1987PubMedGoogle Scholar
  121. 121.
    Sitzmann JV, Abrams R. Improved survival for hepatocellular cancer with combination surgery and multimodality treatment. Ann Surg 217:149, 1993PubMedCrossRefGoogle Scholar
  122. 122.
    Nagasue N, Galizia G, Kohno H, et al. Adverse effects of preoperative hepatic artery chemoembolization for resectable hepatocellular carcinoma: a retrospective comparison of 138 liver resections. Surgery 106:81, 1989PubMedGoogle Scholar
  123. 123.
    Nakamura H, Liu T, Hori S, et al. Response to transcatheter oily chemoembolization in hepatocellular carcinoma 3 cm or less: a study in 50 patients who underwent surgery. Hepatogastroenterology 40:6, 1993PubMedGoogle Scholar
  124. 124.
    Higuchi T, Kikuchi M, Okazaki M. Hepatocellular carcinoma after transcatheter hepatic arterial embolization. Cancer 73:2259, 1994PubMedCrossRefGoogle Scholar
  125. 125.
    Harada T, Matsuo K, Inoue T, et al. Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma? Ann Surg 224:4, 1996PubMedCrossRefGoogle Scholar
  126. 126.
    Lee KC, Kinoshita H, Hirohashi K, Kubo S, Iwasa R. Extension of surgical indications for hepatocellular carcinoma by portal vein embolization. World J Surg 17:109, 1993PubMedCrossRefGoogle Scholar
  127. 127.
    Shimamura T, Nakajima Y, Une Y, et al. Efficacy and safety of preoperative percutaneous transhepatic portal embolization with absolute ethanol: a clinical study. Surgery 121:135, 1997PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Steven A. Curley

There are no affiliations available

Personalised recommendations